Department of CardiologyBeth Israel Deaconess Medical Center
Center for Life Sciences Building, Room 908
3 Blackfan Circle
Boston, MA 02115
Understanding the signaling pathways that mediate cardiac developmental processes may reveal important clues into the cellular and molecular pathogenesis of heart disease. Specifically, we want to understand how protein-tyrosine phosphatases (PTPs) relate to cardiac development and disease. Our lab's research efforts focus on developmental biology, in vivo analysis of in mouse systems, including disease models, and cardiac biology and stem cell research using primary cultures.
Currently, we are studying mouse models in which we can assess the molecular pathogenesis of the congenital cardiac defects associated with Noonan (NS) and LEOPARD (LS) Syndromes, pediatric disorders both attributed primarily to mutations in Shp2. Shp2, encoded by the PTPN11 gene, is a key positive regulator in most, if not all, receptor tyrosine kinase (RTK) signaling pathways, acting upstream of Ras in the Erk/MAP kinase cascade. In this regard, we hope to answer several interesting questions regarding the effects of Shp2 in normal cardiomyocyte development and disease. What is the mechanism by which LS mutations perturb downstream signaling events in the heart, and are other domains in Shp2, such as the tyrosyl phosphorylation sites and the proline-rich stretch, required for the dominant negative effects of the LS mutants? Does deletion of Shp2 have a different effect on cardiomyocyte disease development than the dominant negative (i.e., LS) mutants of Shp2 or does embryonic deletion of Shp2 in the heart have a different phenotype (e.g., HCM) than does post-natal deletion?
In addition, our lab is interested in studying end stage heart failure. Idiopathic dilated cardiomyopathy (IDC) is a disease that results in an enlarged heart that does not pump properly. It is a common reason afflicted individuals require heart transplant surgeries. However, the cause of IDC is unclear and the molecular signaling mechanisms that are aberrantly regulated in IDC are largely unknown. Our recently published work shows that hearts from mice with cardiomyocyte-specific deletion of Shp2, a key positive regulator in most, if not all, receptor tyrosine kinase (RTK) signaling pathways, develop a severe dilated cardiomyopathy (DCM). The loss of Shp2 revealed a hyper-activation in the RhoA signaling pathway, implicating a novel, yet undefined, connection between Shp2 and the RhoA signaling pathway in the heart. RhoA is a small GTP binding protein involved in important cellular functions including cell proliferation, migration, and cytoskeletal reorganization. Recent translational work has demonstrated a significant role for RhoA in cardiovascular disease, including hypertension and atherosclerosis; however, here too, the underlying mechanisms are unclear. In this proposal, we will study elucidate the mechanisms by which RhoA is regulated by Shp2. This project will examine the role of RhoA activity, via Shp2, in cardioprotection of heart failure. This project addresses several interesting and key questions with regards to the function of RhoA in cardiomyocyte disease development: Is RhoA an important regulator of adult cardiac pathogenesis, i.e., in response to stress and/or injury to the heart? What is/are the receptor tyrosine kinase signaling pathway(s) affected by RhoA activity? What is the RhoGEF, RhoGAP and/or other substrate for Shp2 responsible for the dilated phenotype? Can the failure phenotype be rescued with pharmacological intervention?
Finally, our lab is also interested in autoimmunity, particularly in understanding the fundamental mechanisms underlying systemic lupus erythematosus, and the mechanisms therein that lead to aberrant molecular signaling and disease onset. In this model, we have shown that the activity of SHP2 is differentially regulated in SLE, and consequently, have identified a novel cytokine profile responsible for the pathogenicity of the disease. Moreover, our data suggest that inhibition of SHP2 may also be a novel, potent, and specific inhibitor of SLE disease progression. Work is currently underway in understanding the mechanisms for how these processes occur in human and mouse models of SLE.
Last Update: 8/27/2015